Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revance Therapeutics, Inc.

http://www.revance.com/

Latest From Revance Therapeutics, Inc.

Many Firsts Among The Drugs That Launched In 2023

Drug launches in 2023 included some groundbreaking innovations, but that didn’t necessarily translate to quick commercial success.

Innovation Business Strategies

A Year Of Change: Viatris Ploughs Ahead With Brand Ambitions

In 2024, Viatris will initiate the second phase of its long-term business plan, which will see it step away from the perceived volatility of the generics space and begin to move toward innovative and high-growth products. The past year has seen it lay the groundwork for this pivot, shedding surplus business units and making significant hires from the branded space.

Companies Strategy

Galderma Highlights Fast Onset, Durability Data For Potential Botox Rival

The company reported positive data from two Phase IIIb trials testing RelabotulinumtoxinA and said it hopes to refile a BLA for the aesthetic dermatology product soon.

Clinical Trials Business Strategies

Revance Wins First Daxxify Therapeutic Indication, Plans Limited Initial Rollout

Similar to its post-approval strategy in aesthetics less than a year ago, Revance will initially target a small number of doctors as it Daxxify to market in the US for cervical dystonia with a broader launch in 2024.

Approvals Launches
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
      • Topical Delivery
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Essentia Biosystems, Inc.
    • HintMD
UsernamePublicRestriction

Register